Capture ELISA and in vitro cell binding assay for the detection of antibodies to human papillomavirus type 6b virus-like particles in patients with anogenital warts

• Published in: Pathology Vol. 31; no. 4; pp. 418 - 422
• Main Authors: Peng, Shiwen, Qi, Yingmei, Christensen, Neil, Hengst, Kylie, Kennedy, Lynn, Frazer, Ian H., Tindle, Robert W.
• Format: Journal Article
• Language: English
• Published: London Elsevier B.V 01.11.1999; Informa UK Ltd; Taylor and Francis
• Subjects: Adolescent; Adult; Aged; Antibodies, Viral - analysis; Biological and medical sciences; Condylomata Acuminata - virology; DNA, Viral - analysis; Enzyme-Linked Immunosorbent Assay - methods; Female; Genital system. Mammary gland; genital warts; Human papillomavirus; Humans; Immunoglobulin G - blood; Investigative techniques, diagnostic techniques (general aspects); Male; Medical sciences; Middle Aged; Neutralization Tests; Oncogene Proteins, Viral - genetics; Oncogene Proteins, Viral - immunology; Papillomaviridae - genetics; Papillomaviridae - immunology; Papillomaviridae - isolation & purification; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques; Polymerase Chain Reaction; Protein Binding; Reproducibility of Results; Sensitivity and Specificity; serology; Skin Diseases, Infectious - virology; Virion - immunology; VLP; genital warts; Human papillomavirus; VLP; serology; Performance evaluation; Human; Binding; Antibody; Genital system; Human papillomavirus 6; Serology; Papovaviridae; Capture; Genital diseases; Infection; Papillomavirus; Virus; Sexually transmitted disease; Anus; Viral disease; Clinical biology; Digestive diseases; Condyloma acuminatum; Diagnosis; Technique; ELISA assay; Anorectal disease
• ISSN: 0031-3025; 1465-3931
• DOI: 10.1080/003130299104846

To investigate human papillomavirus (HPV) virus-like particle (VLP)-specific antibody responses among anogenital warts patients, a VLP-based capture ELISA was established. Twenty-six percent (35/134) of control subjects and 50.0% (39/78) of patients with current anogenital warts showed IgG seropositivity to HPV 6b VLPs. HPV 6b VLP-specific antibody responses recognised native VLPs only, and had no cross-reaction with HPV type 16 VLPs. No differences in reactivity were observed between L1 and L1 + L2 VLPs, suggesting that L2 contributes little to the total immunogenicity of the papillomavirus virion. A VLP-cell binding assay was also established. Some sera from patients with anogenital warts specifically inhibited VLP binding to the surface of epithelial cells, suggesting that these antibodies might be functionally neutralising. These data show that serological responses to HPV 6b VLPs were induced among some but not all patients with anogenital warts, and give a proportional estimate of infection in the community.